[144] UNITED THERAPEUTICS Corp SEC Filing

Rhea-AI Filing Summary

Form 144 filed for United Therapeutics Corporation (UTHR) reporting proposed and recent insider sales by Martine Rothblatt. The notice lists a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,644,310 and an approximate sale date of 09/19/2025. The shares to be sold were acquired on 03/15/2016 under an executive deferred compensation arrangement totaling 294,000 shares and were originally linked to vested option exercise and payment in common shares. The filing also discloses eight separate common-stock sales by Martine Rothblatt on consecutive dates between 09/09/2025 and 09/18/2025 totaling 36,000 shares with listed gross proceeds for each sale. The filer affirms no undisclosed material adverse information.

Positive

• Disclosure completeness: The filing lists broker, share counts, acquisition date, transaction nature, and per-sale gross proceeds for recent sales.
• Provenance disclosed: Shares were acquired via an executive deferred compensation arrangement on 03/15/2016, clarifying the basis for the sale.

Negative

• Insider selling activity: Martine Rothblatt sold 36,000 shares across 09/09/2025–09/18/2025 and proposes an additional 4,000-share sale, representing insider liquidity.
• Concentration of sales: Multiple sales in consecutive days could be perceived by some market participants as notable selling pressure, though no reasons are stated in the filing.

Insights

Securities Analyst

TL;DR: Insider Martine Rothblatt is undertaking sizable sales: proposed 4,000-share sale plus 36,000 shares sold over prior week.

The filings show routine Rule 144 sales by an insider who acquired shares through an executive deferred compensation arrangement on 03/15/2016. The proposed 4,000-share sale has an indicated aggregate market value of $1,644,310 and will be executed via TD Securities on or about 09/19/2025. The recent eight sales from 09/09/2025–09/18/2025 total 36,000 shares with discrete gross proceeds reported for each transaction. From a market-impact perspective, these are insider disposition disclosures rather than operational updates; they document liquidity events but do not, by themselves, convey company performance information.

Corporate Governance Expert

TL;DR: The Form 144 provides clear disclosure of insider sales and provenance of the shares; it is a compliance filing.

The notice identifies the relationship between the seller and the issuer via the acquisition record (executive deferred compensation) and includes required broker and sale-date details for the proposed transaction. The signer represents no material undisclosed information exists. This filing meets disclosure expectations for Rule 144 notices and documents multiple recent sales by the same insider, which may be of interest to governance reviewers monitoring executive liquidity events, trading plans, and potential aggregation requirements under the rule.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	TD SECURITIES (USA) LLC 125 PARK AVE, 20Th Floor New York NY 10017	4000	1644310.00	45230000	09/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the UTHR Form 144 disclose about proposed sales?

The filing discloses a proposed sale of 4,000 common shares via TD Securities with an aggregate market value of $1,644,310 and an approximate sale date of 09/19/2025.

Who is the seller named on the filing for UTHR?

The seller is Martine Rothblatt, and the filing specifies that the shares were originally acquired under an executive deferred compensation arrangement on 03/15/2016.

How many shares did Martine Rothblatt sell recently according to the filing?

The filing lists eight sales from 09/09/2025 to 09/18/2025 totaling 36,000 shares with gross proceeds reported for each sale.

What broker is handling the proposed UTHR sale?

The proposed sale is to be handled by TD Securities (USA) LLC, located at 125 Park Ave, 20th Floor, New York, NY 10017.

Were the shares being sold purchased with cash?

The filing states the shares were acquired via exercise of vested options with payment made via common shares as part of the executive deferred compensation arrangement on 03/15/2016.